Expert Analysis

New Developments in the Management of Chronic Hepatitis B

Source: CCO Official Conference Coverage of the Shanghai-Hong Kong International Liver Congress 2006

New Developments in the Management of Chronic Hepatitis B

CME Program Director: George K. K. Lau, MD

Faculty:

Nancy W.Y. Leung, MD
Anna S. F. Lok, MD
Guang-bi Yao, MD

CME CREDIT INFORMATION

Release Date: 05/17/06

Expiration Date: 05/16/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent clinical trial data regarding the use of antiretroviral drugs in patients with hepatitis B infection
Identify which patients with hepatitis B infection are likely to benefit from specific therapeutic modalities
Describe the use and effects of peginterferon treatment in Asian patients with hepatitis B infection

Topics covered include:

Durability of Response to Peginterferon in Asian Patients
Peginterferon + Lamivudine in HBeAg-Negative Asian Patients
Entecavir for the Treatment of Chronic Hepatitis B
Adefovir for Treatment of HBeAg-Positive Chinese Patients
Adefovir Safety Analysis
Telbivudine in Chinese Patients
Whom to Treat? The Asian Perspective
When to Stop Treatment
Combination Therapy for the Treatment of Chronic Hepatitis B

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.